Pharming Group N.V. (PHARM.AS)
EUR 0.71
(-4.05%)
EUR 0.71
(-4.05%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 204.24 Million EUR | 25.89% |
| 2022 | 169.82 Million USD | 8.36% |
| 2021 | 156.72 Million EUR | 29.55% |
| 2020 | 120.97 Million EUR | 24.47% |
| 2019 | 97.18 Million EUR | 13.34% |
| 2018 | 85.74 Million EUR | 29.33% |
| 2017 | 66.29 Million EUR | 177.34% |
| 2016 | 23.9 Million EUR | 15.92% |
| 2015 | 20.62 Million EUR | 13.95% |
| 2014 | 18.09 Million EUR | 3.65% |
| 2013 | 17.45 Million EUR | -41.45% |
| 2012 | 29.82 Million EUR | 28.29% |
| 2011 | 23.24 Million EUR | -26.92% |
| 2010 | 31.8 Million EUR | -22.76% |
| 2009 | 41.18 Million EUR | 14.0% |
| 2008 | 36.12 Million EUR | 8304.0% |
| 2007 | -440.31 Thousand EUR | -101.87% |
| 2006 | 23.52 Million EUR | 45.68% |
| 2005 | 16.14 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 63.51 Million USD | -4.18% |
| 2024 Q2 | 69.23 Million EUR | 9.93% |
| 2024 Q3 | 63.92 Million USD | -8.73% |
| 2023 Q3 | 56.45 Million USD | 28.68% |
| 2023 Q2 | 43.87 Million USD | -15.84% |
| 2023 Q4 | 89.64 Million USD | 58.78% |
| 2023 FY | 213.78 Million EUR | 25.89% |
| 2023 Q1 | 52.12 Million USD | -10.93% |
| 2022 Q4 | 58.52 Million USD | 32.74% |
| 2022 FY | 169.82 Million USD | 8.36% |
| 2022 Q1 | 38.91 Million USD | -7.83% |
| 2022 Q2 | 28.29 Million USD | -27.29% |
| 2022 Q3 | 44.09 Million USD | 55.82% |
| 2021 Q1 | 31.46 Million EUR | -21.56% |
| 2021 Q3 | 45.87 Million EUR | 33.94% |
| 2021 Q4 | 42.22 Million EUR | -7.96% |
| 2021 FY | 156.72 Million EUR | 29.55% |
| 2021 Q2 | 34.24 Million EUR | 8.86% |
| 2020 Q4 | 40.1 Million EUR | 39.99% |
| 2020 Q2 | 25.23 Million EUR | -6.45% |
| 2020 Q3 | 28.65 Million EUR | 13.53% |
| 2020 Q1 | 26.97 Million EUR | 0.92% |
| 2020 FY | 120.97 Million EUR | 24.47% |
| 2019 Q4 | 26.73 Million EUR | 19.83% |
| 2019 FY | 97.18 Million EUR | 13.34% |
| 2019 Q1 | 19.71 Million EUR | -24.14% |
| 2019 Q2 | 28.42 Million EUR | 44.16% |
| 2019 Q3 | 22.3 Million EUR | -21.53% |
| 2018 FY | 85.74 Million EUR | 29.33% |
| 2018 Q3 | 20.79 Million EUR | 9.97% |
| 2018 Q2 | 18.91 Million EUR | -5.64% |
| 2018 Q1 | 20.04 Million EUR | -16.25% |
| 2018 Q4 | 25.99 Million EUR | 24.99% |
| 2017 FY | 66.29 Million EUR | 177.34% |
| 2017 Q2 | 15.46 Million EUR | 46.27% |
| 2017 Q3 | 16.33 Million EUR | 5.67% |
| 2017 Q4 | 23.93 Million EUR | 46.47% |
| 2017 Q1 | 10.56 Million EUR | 45.79% |
| 2016 FY | 23.9 Million EUR | 15.92% |
| 2016 Q4 | 7.24 Million EUR | 18.67% |
| 2016 Q3 | 6.1 Million EUR | 17.74% |
| 2016 Q2 | 5.18 Million EUR | -3.14% |
| 2016 Q1 | 5.35 Million EUR | 5.7% |
| 2015 Q2 | 5.89 Million EUR | 42.3% |
| 2015 Q1 | 4.14 Million EUR | -4.54% |
| 2015 FY | 20.62 Million EUR | 13.95% |
| 2015 Q4 | 5.06 Million EUR | -8.18% |
| 2015 Q3 | 5.51 Million EUR | -6.33% |
| 2014 Q2 | 3.91 Million EUR | -12.59% |
| 2014 Q3 | 5.35 Million EUR | 36.78% |
| 2014 FY | 18.09 Million EUR | 3.65% |
| 2014 Q1 | 4.48 Million EUR | -10.47% |
| 2014 Q4 | 4.33 Million EUR | -19.05% |
| 2013 Q3 | 4.31 Million EUR | -3.4% |
| 2013 Q4 | 5 Million EUR | 16.03% |
| 2013 FY | 17.45 Million EUR | -41.45% |
| 2013 Q1 | 3.67 Million EUR | -57.3% |
| 2013 Q2 | 4.46 Million EUR | 21.6% |
| 2012 Q3 | 7.33 Million EUR | 3.38% |
| 2012 FY | 29.82 Million EUR | 28.29% |
| 2012 Q4 | 8.6 Million EUR | 17.23% |
| 2012 Q1 | 6.78 Million EUR | 127.39% |
| 2012 Q2 | 7.09 Million EUR | 4.54% |
| 2011 Q4 | 2.98 Million EUR | -58.69% |
| 2011 Q3 | 7.22 Million EUR | 15.86% |
| 2011 Q2 | 6.23 Million EUR | -8.18% |
| 2011 FY | 23.24 Million EUR | -26.92% |
| 2011 Q1 | 6.79 Million EUR | -23.4% |
| 2010 FY | 31.8 Million EUR | -22.76% |
| 2010 Q4 | 8.86 Million EUR | 38.48% |
| 2010 Q2 | 6.5 Million EUR | -21.36% |
| 2010 Q1 | 8.27 Million EUR | -14.22% |
| 2010 Q3 | 6.4 Million EUR | -1.58% |
| 2009 Q3 | 10.05 Million EUR | -15.38% |
| 2009 FY | 41.18 Million EUR | 14.0% |
| 2009 Q4 | 9.64 Million EUR | -4.02% |
| 2009 Q2 | 11.87 Million EUR | 36.45% |
| 2009 Q1 | 8.7 Million EUR | 0.0% |
| 2008 FY | 36.12 Million EUR | 8304.0% |
| 2007 FY | -440.31 Thousand EUR | -101.87% |
| 2006 FY | 23.52 Million EUR | 45.68% |
| 2005 FY | 16.14 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.17 Million EUR | -4789.868% |
| ABIVAX Société Anonyme | 127.37 Million EUR | -60.352% |
| Adocia SA | 15.62 Million EUR | -1206.864% |
| Aelis Farma SA | 18.81 Million EUR | -985.338% |
| Biophytis S.A. | 14.33 Million EUR | -1325.031% |
| Advicenne S.A. | 8.21 Million EUR | -2386.302% |
| genOway Société anonyme | 16.73 Million EUR | -1120.255% |
| IntegraGen SA | 5.35 Million EUR | -3715.962% |
| Medesis Pharma S.A. | 1.56 Million EUR | -12954.672% |
| Neovacs S.A. | 10.34 Million EUR | -1874.659% |
| NFL Biosciences SA | 4.37 Million EUR | -4569.256% |
| Plant Advanced Technologies SA | 2.76 Million EUR | -7287.372% |
| Quantum Genomics Société Anonyme | 1.71 Million EUR | -11789.052% |
| Sensorion SA | 27.05 Million EUR | -654.979% |
| Theranexus Société Anonyme | 3 Million EUR | -6697.026% |
| TME Pharma N.V. | 5.49 Million EUR | -3615.658% |
| Valbiotis SA | 9.86 Million EUR | -1969.609% |
| TheraVet SA | 1.64 Million EUR | -12321.586% |
| Valerio Therapeutics Société anonyme | 20.32 Million EUR | -905.166% |
| argenx SE | 1.34 Billion EUR | 84.788% |
| BioSenic S.A. | 7.58 Million EUR | -2593.522% |
| Celyad Oncology SA | 8.49 Million EUR | -2305.769% |
| DBV Technologies S.A. | 89.4 Million EUR | -128.452% |
| Galapagos NV | 327.98 Million EUR | 37.726% |
| Genfit S.A. | 54.8 Million EUR | -272.691% |
| GeNeuro SA | 14.35 Million EUR | -1322.619% |
| Hyloris Pharmaceuticals SA | 17.98 Million EUR | -1035.541% |
| Innate Pharma S.A. | 64.57 Million EUR | -216.323% |
| Inventiva S.A. | 120.18 Million EUR | -69.945% |
| MaaT Pharma SA | 21.59 Million EUR | -845.688% |
| MedinCell S.A. | 32.92 Million EUR | -520.405% |
| Nanobiotix S.A. | 58.92 Million EUR | -246.615% |
| Onward Medical N.V. | 20.64 Million EUR | -889.342% |
| Oryzon Genomics S.A. | 18.49 Million EUR | -1004.225% |
| OSE Immunotherapeutics SA | 23.58 Million EUR | -765.869% |
| Oxurion NV | 12.21 Million EUR | -1572.259% |
| Poxel S.A. | 28.76 Million EUR | -610.063% |
| GenSight Biologics S.A. | 32.66 Million EUR | -525.382% |
| Transgene SA | 31.23 Million EUR | -553.997% |
| Financière de Tubize SA | 114.38 Thousand EUR | -178457.158% |
| UCB SA | 2.94 Billion EUR | 93.055% |
| Valneva SE | 134.92 Million EUR | -51.381% |
| Vivoryon Therapeutics N.V. | 24.69 Million EUR | -727.19% |